This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kobayashi, K. Articles by Chiba, K. Search for Related Content PubMed PubMed Citation Articles by Kobayashi, K. Articles by Chiba, K.

Role of Human Cytochrome P450 3A4 in Metabolism of Medroxyprogesterone Acetate

Laboratory of Biochemical Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Chiba University, Chiba 263-8522 [K. K., N. M., K. C.]; Division of Oncology, Department of Medicine, National Cancer Center Hospital East, Chiba 277-8577 [H. F., H. M., Y. S.]; and Materials Technology Research Laboratories, Daiichi Pure Chemicals Co. Ltd., Ibaraki 319-1182 [N. S.], Japan

Medroxyprogesterone acetate (MPA) is a drug commonly used in endocrine therapy for advanced or recurrent breast cancer and endometrial cancer. The drug is extensively metabolized in the intestinal mucosa and in the liver. Cytochrome P450s (CYPs) involved in the metabolism of MPA were identified by using human liver microsomes and recombinant human CYPs. In this study, the overall metabolism of MPA was determined as the disappearance of the parent drug from an incubation mixture. The disappearance of MPA in human liver microsomes varied 2.6-fold among the 18 samples studied. The disappearance of MPA in the same panel of 18 human liver microsomes was significantly correlated with triazolam -hydroxylase activity, a marker activity of CYP3A (r = 0.764; P < 0.001). Ketoconazole, an inhibitor of CYP3A4, potently inhibited the disappearance of MPA in 18 human liver microsomes. Anti-CYP3A antibody also inhibited 86% of the disappearance of MPA in human liver microsomes. Although sulfaphenazole (an inhibitor of CYP2C9) and S-mephenytoin (an inhibitor of CYP2C19) partially inhibited the disappearance of MPA, no effect of the anti-CYP2C antibody was observed. The disappearance of MPA did not correlate with either the activity metabolized via CYP2C9 (diclofenac 4'-hydroxylase activity) or the activity metabolized via CYP2C19 (S-mephenytoin 4'-hydroxylase activity). Among the 12 recombinant human CYPs (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5) studied, only CYP3A4 showed metabolic activity of MPA. These results suggest that CYP3A4 is mainly involved in the overall metabolism of MPA in human liver microsomes.

This article has been cited by other articles:

				J.-W. Zhang, Y. Liu, J.-Y. Zhao, L.-M. Wang, G.-B. Ge, Y. Gao, W. Li, H.-T. Liu, H.-X. Liu, Y.-Y. Zhang, et al. Metabolic Profiling and Cytochrome P450 Reaction Phenotyping of Medroxyprogesterone Acetate Drug Metab. Dispos., November 1, 2008; 36(11): 2292 - 2298. [Abstract] [Full Text] [PDF]

				S. Sharma, J. Ou, S. Strom, D. Mattison, S. Caritis, and R. Venkataramanan Identification of Enzymes Involved in the Metabolism of 17{alpha}-Hydroxyprogesterone Caproate: An Effective Agent for Prevention of Preterm Birth Drug Metab. Dispos., September 1, 2008; 36(9): 1896 - 1902. [Abstract] [Full Text] [PDF]

				H. Masuyama, H. Nakatsukasa, N. Takamoto, and Y. Hiramatsu Down-Regulation of Pregnane X Receptor Contributes to Cell Growth Inhibition and Apoptosis by Anticancer Agents in Endometrial Cancer Cells Mol. Pharmacol., October 1, 2007; 72(4): 1045 - 1053. [Abstract] [Full Text] [PDF]

				M. Katoh, T. Matsui, M. Nakajima, C. Tateno, M. Kataoka, Y. Soeno, T. Horie, K. Iwasaki, K. Yoshizato, and T. Yokoi EXPRESSION OF HUMAN CYTOCHROMES P450 IN CHIMERIC MICE WITH HUMANIZED LIVER Drug Metab. Dispos., December 1, 2004; 32(12): 1402 - 1410. [Abstract] [Full Text] [PDF]

				C. Tateno, Y. Yoshizane, N. Saito, M. Kataoka, R. Utoh, C. Yamasaki, A. Tachibana, Y. Soeno, K. Asahina, H. Hino, et al. Near Completely Humanized Liver in Mice Shows Human-Type Metabolic Responses to Drugs Am. J. Pathol., September 1, 2004; 165(3): 901 - 912. [Abstract] [Full Text] [PDF]

				K. Kobayashi, K. Urashima, N. Shimada, and K. Chiba SELECTIVITIES OF HUMAN CYTOCHROME P450 INHIBITORS TOWARD RAT P450 ISOFORMS: STUDY WITH cDNA-EXPRESSED SYSTEMS OF THE RAT Drug Metab. Dispos., July 1, 2003; 31(7): 833 - 836. [Abstract] [Full Text] [PDF]